Dr. Ankur Bahl
Experience: Over 22 years
Fortis Memorial Research Institute (FMRI)
Gurugram, India
Introduction
Dr. Ankur Bahl is the Principal Director of Medical Oncology at FMRI. Patients usually end up in his clinic when a biopsy confirms breast or lung cancer, when a tough head and neck tumor requires targeted therapy, or when dealing with complex blood cancers like leukemia and lymphoma.
About Dr. Ankur Bahl
Dr. Ankur Bahl has been treating solid and blood cancers for over twenty-two years. He actually holds a brilliant academic record, winning the Dr. Rehan Gold Medal for being the best postgraduate student during his MD. Then took his expertise global, picking up a highly specialized certification in drug interactions and pharmacovigilance directly from the University of Oxford.
He actually published the largest real-world Indian data study on using targeted therapy (Cetuximab) for head and neck cancers. Also heavily involved in teaching the medical community. Founded live oncology tumor boards and master classes to train the next generation of cancer doctors. Before taking the lead at Fortis, he was the Director of Medical Oncology at Max Hospital in Saket and spent vital years at the Rajiv Gandhi Cancer Institute.
Qualifications
- MBBS — Maulana Azad Medical College, New Delhi.
- MD (Internal Medicine) — Maulana Azad Medical College, New Delhi (Dr. Rehan(Gold Medalist).
- DM (Medical Oncology) — AIIMS, New Delhi.
- Pharmacovigilance & Drug Interactions Certification — University of Oxford, UK.
Awards & Recognition
- Principal Director of Medical Oncology at FMRI.
- Dr. Rehan Gold Medal for Best Outgoing Postgraduate Student.
- Lead author of India’s largest study on targeted therapy for head and neck cancer.
- Founder of Live Oncology Tumor Boards and Master Classes.
- Previously Director of Medical Oncology at Max Hospital, Saket.
- Member of ASCO, ESMO, and ISMPO.
Specialities & Expertise
- Targeted therapy and immunotherapy
- Head and neck cancer treatment
- Breast and lung cancer oncology
- GI and gynecological cancers
- Leukemia, lymphoma, and multiple myeloma
- Tumor genomics and precision medicine
Patient Experience & Approach
Breast and lung cancer patients say Dr. Ankur Bahl doesn’t just hand them a generic chemo plan. He actually explains how their specific tumor genomics dictate whether targeted therapy or immunotherapy will work better for their exact body. His background at AIIMS shows in how honestly he discusses what the survival odds and quality of life realistically look like.